[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07447206":3,"trial-entities:NCT07447206":113,"trial-summary:NCT07447206":118},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":22,"study_type":28,"primary_purpose":29,"phases":30,"enrollment_info":32,"interventions":35,"primary_outcomes":46,"secondary_outcomes":51,"sex":59,"minimum_age":60,"maximum_age":61,"healthy_volunteers":15,"eligibility_criteria":62,"std_ages":91,"locations":94,"central_contacts":104,"overall_officials":110,"references":111,"see_also_links":112},"NCT07447206","HS-24-00340","Vascular Intervention Strategies Trial for Alzheimer's","Vascular Intervention Strategies Trial for Alzheimer's (VISTA)","NOT_YET_RECRUITING","2028-06","2026-04","2026-05-04","2026-05","University of Southern California","OTHER",false,"The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. All participants will receive angiotensin receptor blockers (ARBs) for high blood pressure, and hydrophilic statins (or a non-statin alternative) for high cholesterol over a six-month period.",null,[19,20,21],"Hypertension","Hypercholesterolemia","Dementia Risk Factors",[23,24,19,20,25,26,27],"APOE ε4 carriers","Dementia risk","Vascular risk factors","Pharmacist-led intervention","Feasibility study","INTERVENTIONAL","TREATMENT",[31],"PHASE2",{"count":33,"type":34},10,"ESTIMATED",[36,42],{"type":37,"name":38,"description":39,"armGroupLabels":40},"DRUG","Angiotensin Receptor Blockers (ARBs)","Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes blood pressure management with angiotensin receptor blockers (ARBs).",[41],"Pharmacist-Led Vascular Risk Factor Management",{"type":37,"name":43,"description":44,"armGroupLabels":45},"Hydrophilic Statins or Non-Statin Alternative","Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes cholesterol management with hydrophilic statins or a non-statin alternative if statins are not appropriate.",[41],[47],{"measure":48,"description":49,"timeFrame":50},"Blood Pressure Control","Change in systolic blood pressure (mmHg) from baseline to the end of the 6-month intervention.","Baseline to 6 months",[52,55],{"measure":53,"description":54,"timeFrame":50},"Lipid Level Changes","Change in LDL cholesterol (mg\u002FdL) from baseline to 6 months.",{"measure":56,"description":57,"timeFrame":58},"Feasibility Metrics","adherence to prescribed medications (%).","Study duration (6 months)","ALL","50 Years","75 Years",{"inclusion":63,"exclusion":71,"raw_text":90},[64,65,66,67,68,69,70],"APOE ε4 carrier (homozygote or heterozygote)","LDL-C of 100-250 mg\u002FdL","Systolic blood Pressure (SBP) 130-180 mm Hg","Age 50-75 years","Fluency in English","No dementia based on medical record review","Male or post-menopausal female",[72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89],"One minute standing SBP \\\u003C 110 mm Hg","Arm circumference prevents from accurate BP measurement with use of available devices","Lost weight of \\> 10% unintendedly (within the past 6 months),","Contraindications to blood pressure and cholesterol lowering medications","Use of medications prescribed for dementia (e.g., aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, memantine)","Evidence of dementia based on medical record review","Living in a skilled nursing or rehabilitation facility","Receiving palliative or hospice care","Bipolar illness or schizophrenia","Drug or alcohol disorder","Receiving chronic opioid therapy","Any significant neurological disease (e.g., Parkinson's disease, amyotrophic lateral sclerosis, or multiple sclerosis)","Severe loss of visual, hearing or communication ability","Organ transplant","History of stroke, symptomatic HF or left ventricular ejection fraction \\\u003C 35%","ESRD or eGFR \\\u003C 20 ml\u002Fmin \u002F1.73m2","Does not consent to be contacted or to have their medical record reviewed for research purposes","Concurrent participation in another clinical trial","Inclusion Criteria:\n\n* APOE ε4 carrier (homozygote or heterozygote)\n* LDL-C of 100-250 mg\u002FdL\n* Systolic blood Pressure (SBP) 130-180 mm Hg\n* Age 50-75 years\n* Fluency in English\n* No dementia based on medical record review\n* Male or post-menopausal female\n\nExclusion Criteria:\n\n* One minute standing SBP \\\u003C 110 mm Hg\n* Arm circumference prevents from accurate BP measurement with use of available devices\n* Lost weight of \\> 10% unintendedly (within the past 6 months),\n* Contraindications to blood pressure and cholesterol lowering medications\n* Use of medications prescribed for dementia (e.g., aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, memantine)\n* Evidence of dementia based on medical record review\n* Living in a skilled nursing or rehabilitation facility\n* Receiving palliative or hospice care\n* Bipolar illness or schizophrenia\n* Drug or alcohol disorder\n* Receiving chronic opioid therapy\n* Any significant neurological disease (e.g., Parkinson's disease, amyotrophic lateral sclerosis, or multiple sclerosis)\n* Severe loss of visual, hearing or communication ability\n* Organ transplant\n* History of stroke, symptomatic HF or left ventricular ejection fraction \\\u003C 35%\n* ESRD or eGFR \\\u003C 20 ml\u002Fmin \u002F1.73m2\n* Does not consent to be contacted or to have their medical record reviewed for research purposes\n* Concurrent participation in another clinical trial",[92,93],"ADULT","OLDER_ADULT",[95],{"facility":96,"city":97,"state":98,"zip":99,"country":100,"geoPoint":101},"Clinical Sciences Building (CSC)","Los Angeles","California","90033","United States",{"lat":102,"lon":103},34.05223,-118.24368,[105],{"name":106,"role":107,"phone":108,"email":109},"Hussein Yassine, MD","CONTACT","(323) 442-0272","hyassine@usc.edu",[],[],[],{"nct_id":4,"conditions":114,"biomarkers":116},[115,20,19],"Dementia",[117],"APOE Gene",{"nct_id":4,"found":119,"summary":120,"prompt_version":129},true,{"design":121,"status":122,"heading":6,"summary":123,"follow_up":124,"word_count":125,"commitments":126,"compensation":127,"drugs_mentioned":128},"This is an interventional pilot study with 10 participants. All participants will receive the same treatments.","completed","This study is looking at how managing blood pressure and cholesterol might help people at risk for dementia. It's a small pilot study with 10 participants, aged 50-75, who carry a specific gene (APOE ε4) linked to dementia risk. You would receive pharmacist-led care for six months. This care includes medication for high blood pressure, specifically Angiotensin Receptor Blockers (ARBs), and medication for high cholesterol, either Hydrophilic Statins or a non-statin alternative. The main goal is to see how well blood pressure is controlled during this six-month period. The study is currently unclear on its recruitment status.","The primary endpoint, blood pressure control, is measured from the start of the study up to 6 months.",97,"You would receive pharmacist-led management of your blood pressure and cholesterol over a six-month period.","Not stated in the trial record.",[38],"v2"]